Burrows Scott L sold $184K of SYRE
Burrows Scott L (Chief Financial Officer) sold 2,599 shares of Spyre Therapeutics, Inc. (SYRE) at $70.77 ($0.18M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
Insider selling disclosed via Form 4; likely limited incremental fundamental signal given 10b5-1 pre-arrangement.
Spyre Therapeutics CFO Burrows Scott L sold $183,931 of SYRE shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Near-term impact likely muted; any reaction may be sentiment-driven rather than fundamental.
Background
This is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics (SYRE).
Why it matters
The disclosure provides a datapoint on insider activity but does not introduce new company-specific fundamentals (no earnings, trial, deal, or regulatory action mentioned).
Market relevance
Traders may monitor for follow-on insider activity, but the 10b5-1 structure generally limits immediate trading signal strength.
Market effects
Minimal—single-company insider transaction with no stated operational/regulatory catalyst.
None.
None.
Alternative perspectives
Because the sale is pre-arranged, it could be mechanically timed around liquidity needs without reflecting negative outlook.
The filing does not disclose reasons for sale; traders should avoid over-interpreting 10b5-1 transactions as bearish fundamentals.
Key entities
- issuerSpyre Therapeutics, Inc.
SYRE, subject of the Form 4 insider sale by its CFO.
- insiderBurrows Scott L
CFO who sold 2,599 SYRE shares at $70.7700 under a 10b5-1 plan.
